Understanding the Potential Impact of Different Drug Properties On SARS-CoV-2 Transmission and Disease Burden: A Modelling Analysis.
Whittaker C., Watson OJ., Alvarez-Moreno C., Angkasekwinai N., Boonyasiri A., Carlos Triana L., Chanda D., Charoenpong L., Chayakulkeeree M., Cooke GS., Croda J., Cucunubá ZM., Djaafara BA., Estofolete CF., Grillet M-E., Faria NR., Figueiredo Costa S., Forero-Peña DA., Gibb DM., Gordon AC., Hamers RL., Hamlet A., Irawany V., Jitmuang A., Keurueangkul N., Kimani TN., Lampo M., Levin AS., Lopardo G., Mustafa R., Nayagam S., Ngamprasertchai T., Njeri NIH., Nogueira ML., Ortiz-Prado E., Perroud MW., Phillips AN., Promsin P., Qavi A., Rodger AJ., Sabino EC., Sangkaew S., Sari D., Sirijatuphat R., Sposito AC., Srisangthong P., Thompson HA., Udwadia Z., Valderrama-Beltrán S., Winskill P., Ghani AC., Walker PGT., Hallett TB.
BACKGROUND: The public health impact of the COVID-19 pandemic has motivated a rapid search for potential therapeutics, with some key successes. However, the potential impact of different treatments, and consequently research and procurement priorities, have not been clear. METHODS: Using a mathematical model of SARS-CoV-2 transmission, COVID-19 disease and clinical care, we explore the public-health impact of different potential therapeutics, under a range of scenarios varying healthcare capacity, epidemic trajectories; and drug efficacy in the absence of supportive care. RESULTS: The impact of drugs like dexamethasone (delivered to the most critically-ill in hospital and whose therapeutic benefit is expected to depend on the availability of supportive care such as oxygen and mechanical ventilation) is likely to be limited in settings where healthcare capacity is lowest or where uncontrolled epidemics result in hospitals being overwhelmed. As such, it may avert 22% of deaths in high-income countries but only 8% in low-income countries (assuming R=1.35). Therapeutics for different patient populations (those not in hospital, early in the course of infection) and types of benefit (reducing disease severity or infectiousness, preventing hospitalisation) could have much greater benefits, particularly in resource-poor settings facing large epidemics. CONCLUSIONS: Advances in the treatment of COVID-19 to date have been focussed on hospitalised-patients and predicated on an assumption of adequate access to supportive care. Therapeutics delivered earlier in the course of infection that reduce the need for healthcare or reduce infectiousness could have significant impact, and research into their efficacy and means of delivery should be a priority.